Media stories about Heron Therapeutics (NASDAQ:HRTX) have trended somewhat positive this week, according to Accern. The research firm ranks the sentiment of press coverage by analyzing more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Heron Therapeutics earned a news sentiment score of 0.23 on Accern’s scale. Accern also gave press coverage about the biotechnology company an impact score of 46.7815597919223 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the next few days.
These are some of the news stories that may have impacted Accern Sentiment’s analysis:
- Highland Capital Management LP Has Decreased Heron Therapeutics (HRTX) Position; Inverness Counsel Lowered … – Hill Country Times (hillcountrytimes.com)
- Free Research Reports on These Drug Makers Stocks — Novartis, Heron Therapeutics, Aerie Pharma, and Pfizer (bizjournals.com)
- Heron Therapeutics (HRTX) Upgraded to “Hold” by ValuEngine (americanbankingnews.com)
- Heron Therapeutics, Inc. (HRTX) Given Consensus Recommendation of “Buy” by Analysts (americanbankingnews.com)
- $7.98 Million in Sales Expected for Heron Therapeutics, Inc. (HRTX) This Quarter (americanbankingnews.com)
Several equities research analysts recently issued reports on HRTX shares. Cantor Fitzgerald set a $31.00 price target on shares of Heron Therapeutics and gave the company a “buy” rating in a report on Thursday, October 26th. ValuEngine raised shares of Heron Therapeutics from a “sell” rating to a “hold” rating in a report on Thursday. Jefferies Group reissued a “buy” rating on shares of Heron Therapeutics in a report on Wednesday, August 16th. Northland Securities began coverage on shares of Heron Therapeutics in a report on Wednesday, September 27th. They set an “outperform” rating and a $40.00 target price on the stock. Finally, Noble Financial reissued a “buy” rating and set a $24.00 target price on shares of Heron Therapeutics in a report on Friday, October 6th. Two analysts have rated the stock with a hold rating and eleven have given a buy rating to the stock. The company currently has an average rating of “Buy” and an average target price of $28.73.
Heron Therapeutics (NASDAQ:HRTX) last released its earnings results on Monday, November 6th. The biotechnology company reported ($0.77) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.87) by $0.10. Heron Therapeutics had a negative net margin of 831.89% and a negative return on equity of 385.11%. The company had revenue of $8.57 million for the quarter, compared to the consensus estimate of $8.12 million. analysts forecast that Heron Therapeutics will post -3.42 earnings per share for the current year.
TRADEMARK VIOLATION WARNING: “Heron Therapeutics (HRTX) Earns Daily News Sentiment Rating of 0.23” was reported by Community Financial News and is the property of of Community Financial News. If you are accessing this story on another domain, it was illegally stolen and republished in violation of U.S. and international trademark and copyright laws. The legal version of this story can be read at https://www.com-unik.info/2017/12/03/heron-therapeutics-hrtx-earns-daily-news-sentiment-rating-of-0-23.html.
About Heron Therapeutics
Heron Therapeutics, Inc is a biotechnology company engaged in developing pharmaceutical products for patients suffering from cancer or pain. The Company’s product candidates include SUSTOL, HTX-019 and HTX-011. All of its product candidates utilize science and technology platforms, including its Biochronomer drug delivery technology.
What are top analysts saying about Heron Therapeutics Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Heron Therapeutics Inc. and related companies.